Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419328
Status:
COMPLETED
Last Update Posted:
2022-07-21
First Post:
2007-01-05
Brief Title:
A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors
Sponsor:
AGC Biologics SpA
Organization:
AGC Biologics SpA
Study Overview
Official Title:
NGR002 A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors Definition of an Optimal Biological Dose
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of the trial is to explore the safety and biological activity of NGR-hTNF The safety will be established by clinical and laboratory assessment The biological activity will be evaluated by DCE-MRI with contrast media
Detailed Description:
This is a modified phase I Single arm open non randomized trial of NGR-hTNF in advanced solid tumors for the definition of an optimal biological
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-002194-23 | EUDRACT_NUMBER | None | None |